Provectus Biopharmaceuticals, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, with the SEC on November 10, 2026, disclosing a net loss of $3,563,375 for the nine months ended September 30, 2026.

Key Highlights

  • Nine-month net loss: The company reported a net loss of $3,563,375 for the nine months ended September 30, 2026, compared to $4,337,312 in the same period of 2025.
  • Third-quarter net loss: Net loss for the three months ended September 30, 2026 was $1,273,710, versus $1,323,629 for the same quarter in 2025.
  • Cash position: Cash on hand was $180,733 as of September 30, 2026, down from $251,291 as of December 31, 2025.
  • Total assets: Total assets were $467,087 at September 30, 2026, compared to $697,502 at December 31, 2025.
  • Stockholders' deficit: Total stockholders' deficit was $(6,679,069) at September 30, 2026, compared to $(6,302,718) at December 31, 2025.
  • Accumulated deficit: The accumulated deficit reached $266,393,108 as of September 30, 2026, up from $262,853,812 at December 31, 2025.
  • Shares outstanding: 420,279,879 shares of common stock, par value $0.001, were issued and outstanding as of November 10, 2026.

Provectus Biopharmaceuticals Financial Condition for the Nine Months Ended September 30, 2026

According to the filing, Provectus Biopharmaceuticals, Inc. reported a net loss of $3,563,375 for the nine months ended September 30, 2026, a reduction from the $4,337,312 net loss recorded in the comparable 2025 period. The company disclosed zero grant revenue for the first nine months of 2026, compared to $336,108 in grant revenue reported for the same period in 2025. Total operating expenses for the nine months ended September 30, 2026 were $3,397,946, consisting of $704,784 in research and development expenses and $2,693,162 in general and administrative expenses.

The filing shows the company's balance sheet deteriorated over the reporting period. Total assets fell to $467,087 at September 30, 2026, from $697,502 at December 31, 2025, with cash declining to $180,733. Total current liabilities were $7,105,465 as of September 30, 2026, including convertible notes payable of $1,775,000 and convertible notes payable to related parties of $980,000. Other accrued expenses stood at $3,452,993. The company's securities are listed as "None" under Section 12(b) of the Act, with no exchange registration disclosed on the cover page.

The filing notes that Provectus carries Series D and Series D-1 Convertible Preferred Stock. As of September 30, 2026, Series D-1 shares issued and outstanding were 14,948,583, with an aggregate liquidation preference of $245,611,056. The noncontrolling interest in subsidiary was $(19,827) at September 30, 2026. The company's forward-looking statements, as disclosed in the filing, are subject to risks including uncertainty around its rose bengal sodium-based drug product candidates and its ability to raise additional capital, among other factors cited in the filing's cautionary language.

What Was Disclosed

Provectus Biopharmaceuticals filed its Form 10-Q for the quarter ended September 30, 2026, reporting a nine-month net loss of $3,563,375, cash of $180,733, a total stockholders' deficit of $(6,679,069), and an accumulated deficit of $266,393,108, with no exchange-listed securities.